Artesunate monitoring — DTM&H MCQ

Correct answer: C — Check for delayed haemolysis

Check for delayed haemolysis (option C) is correct because post-artesunate delayed haemolysis (PADH) is a well recognised complication occurring 7 to 21 days after intravenous artesunate for severe falciparum malaria, affecting roughly 10 to 15 percent of treated adults, particularly those with high initial parasite counts. It results from the delayed clearance of once-infected, artesunate-pitted red cells by the spleen, causing haemolysis after the parasites have already been cleared. The presentation of fatigue, dark urine and a falling haemoglobin two weeks after treatment is the classic pattern, and UK guidance specifically recommends routine haemoglobin monitoring at around day 14 post-artesunate for this reason. The correct action is therefore to actively investigate for haemolysis (full blood count, reticulocytes, LDH, haptoglobin, bilirubin, direct antiglobulin test) rather than assume relapse or an unrelated cause. Why the other options are wrong: B. Repeat yellow fever serology: there is no exposure history or clinical feature suggesting yellow fever, and this does not explain haemolysis specifically linked to artesunate use. D. Start empirical rifampicin: rifampicin treats mycobacterial or some bacterial infections and has no role in a haemolytic anaemia following antimalarial treatment; empirical antibiotics are not indicated without evidence of bacterial co-infection. E. Perform skin snip microscopy: this diagnoses onchocerciasis, which causes dermatitis and eye disease, not acute haemolytic anaemia after artesunate. A. Measure faecal calprotectin: this is a marker of intestinal inflammation used in suspected inflammatory bowel disease, irrelevant to dark urine and anaemia after antimalarial therapy. Key point: any patient treated with intravenous artesunate for severe malaria needs haemoglobin monitoring around day 7 to 14 because delayed haemolysis is a common, self-limiting but potentially significant complication that requires active surveillance, not assumption of relapse.

Reference: UK malaria treatment guidelines 2016 (PHE/British Infection Association), Journal of Infection 2016; recommends haemoglobin checked approximately 14 days after completing intravenous artesunate due to delayed haemolysis risk. https://www.journalofinfection.com/article/S0163-4453(16)00047-5/fulltext